Document Detail

Effects of prostacyclin infusion on blood pressure and plasma renin activity in patients with essential hypertension.
MedLine Citation:
PMID:  1536471     Owner:  NLM     Status:  MEDLINE    
The effects of prostacyclin infusion (6.7 +/- 2.7 ng/kg/min, 3 to 10 ng/kg/min) on blood pressure, plasma renin activity (PRA), and 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) were studied in 7 patients with essential hypertension (4 men and 3 women) with a mean age of fifty-eight +/- eleven years (forty-six to seventy-four years). The baseline value of 6-keto-PGF1 alpha for patients with essential hypertension was not lower than in healthy subjects. Blood pressure immediately dropped following prostacyclin infusion. Systolic blood pressure returned to the baseline value after prostacyclin infusion was discontinued. However, diastolic blood pressure and mean arterial blood pressure were still significantly decreased thirty minutes after termination of infusion. Heart rate did not change during prostacyclin infusion but decreased significantly when infusion was terminated. PRA was not significantly affected by prostacyclin infusion. The 6-keto-PGF1 alpha level was about 8 times higher than the baseline value thirty minutes after initiation of prostacyclin infusion and approximately twice as high as the baseline value thirty minutes after termination of infusion. The decrease in mean arterial blood pressure coincided with the increase in 6-keto-PGF1 alpha. There was no correlation between mean arterial blood pressure and PRA, nor between PRA and 6-keto-PGF1 alpha. These results demonstrate that production of prostacyclin is not reduced in patients with essential hypertension, and heart rate and PRA are not changed by prostacyclin infusion, although prostacyclin decreases blood pressure.
T Kato; S Yoneda; M Koketsu; T Fujinami
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Angiology     Volume:  43     ISSN:  0003-3197     ISO Abbreviation:  Angiology     Publication Date:  1992 Feb 
Date Detail:
Created Date:  1992-03-23     Completed Date:  1992-03-23     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0203706     Medline TA:  Angiology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  110-20     Citation Subset:  IM    
Department of Anesthesiology, Toyokawa City Hospital, Aichi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
6-Ketoprostaglandin F1 alpha / blood
Analysis of Variance
Blood Pressure / drug effects*
Drug Evaluation
Epoprostenol / administration & dosage*
Hypertension / blood,  drug therapy*,  physiopathology
Infusions, Intravenous
Middle Aged
Regression Analysis
Renin / blood,  drug effects*
Time Factors
Reg. No./Substance:
35121-78-9/Epoprostenol; 58962-34-8/6-Ketoprostaglandin F1 alpha; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Blood flow asymmetry in carotid occlusive disease.
Next Document:  Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled doub...